Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Adjuvant radiotherapy may be beneficial in treating locally advanced prostate cancer

Although in most cases prostate cancer can be cured, approximately 900 men every year die of it.

Treatment recommendations for prostate cancer are largely based on the cancer's stage (TNM classification), the cancer's aggressiveness determined from a prostate biopsy (the Gleason score), and prostate-specific antigen (PSA) obtained from a blood test, as well as the risk categorisation determined on the basis of these.

The treatment options for a local, low-risk prostate cancer are established and the prognosis is good.

On the other hand, the prognosis for a higher-risk, locally spread or metastasised cancer is poorer, and there is no consensus on the treatments due to a lack of sufficient research data.

In connection to the surgical removal of the prostate, the cancer may be found to have extended to the surface of the removed prostate or to have already spread through the capsule surrounding the prostate.

In such cases, the risk of recurrence is higher than in situations in which the cancer cells are confined within the prostate.

The Finnish FinnProstataX study published in the journal European Urology investigated whether radiotherapy administered after the removal of the prostate benefited patients whose cancer had spread to the surface of the prostate or beyond the capsule that surrounds the prostate.

At the moment, treatment practices in these situations vary.

The randomised study carried out in 2004 - 2012 included 250 patients.

Of these 250 patients, 126 received adjuvant radiotherapy after the removal of the prostate, while the treatment of 124 patients consisted of the mere removal of the prostate.

Over the roughly nine-year follow-up, only two patients - one from each group - died of prostate cancer.

Based on PSA measurements, 82 per cent of the members of the adjuvant treatment group were disease-free at the end of the follow-up period; the equivalent percentage in the control group was 61.

An increase in the PSA value usually precedes the recurrence of prostate cancer, and in the study, the patients with a maximum PSA of 0.4ug/l were determined to be disease-free.

No metastases were detected in 98 percent of those in the adjuvant treatment group and 96 percent of those in the control group during the follow-up period.

"Tolerance for the adjuvant treatment was good, and it prolonged the disease-free period measured from the PSA compared to the mere surgical removal of the prostate. Even so, the adjuvant treatment did not extend patients' survival," said professor Akseli Hemminki, summing up the results of the study.

"Prostate cancer may generate metastases and, in the worst case, result in death more than 10 years after the recurrence of the disease, detected from a PSA increase. Given that the patients in this study were monitored for less than 10 years on average, it's only natural that the treatment we studied did not have a significant impact on survival. In even longer follow-up, a difference in PSA increases could also lead to a difference in mortality," explained the article's lead author, Greetta Hackman.

Hackman stresses that when making treatment decisions, it is important to discuss the available options openly with the patient.

"More treatment also means more side effects. However, at the same time, we can likely influence the disease's prognosis in a situation in which the cancerous tissue already extends to the prostate's surface or has penetrated through the prostate's capsule, but has not yet metastasised," added Hackman. 

Source: University of Helsinki

0

Comments

Please click on the 'New Comment' link to the left to add a new comment, or alternatively click any 'Add Comment' link next to any existing post to respond. The views expressed here are not those of ecancer. For more information please view our Privacy Policy.



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation